name: Huntington's Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-02-27T22:30:28Z'
category: Genetic
parents:
- Neurodegenerative Disorder
- Movement Disorder
synonyms:
- Huntington's Chorea
has_subtypes:
- name: Juvenile Huntington's Disease
  description: A rare, early-onset form that begins in childhood or adolescence
    and progresses more rapidly than typical forms.
  evidence:
  - reference: PMID:26557176
    supports: SUPPORT
    snippet: Huntington's disease (HD) is a rare dominantly inherited
      neurodegenerative disorder... As is expected in a case of childhood-onset
      HD, our patient is rapidly deteriorating and is currently in the terminal
      phase of his illness along with resistant convulsions.
    explanation: The abstract describes a case of childhood-onset Huntington's
      disease that progresses rapidly, supporting the statement.
  - reference: PMID:36318082
    supports: SUPPORT
    snippet: Juvenile-onset Huntington's disease (JOHD) is a rare form of
      Huntington's disease (HD) characterized by symptom onset before the age of
      21 years... The mean annualized decrease in striatal volume in the JOHD
      group was -3.99% compared to -0.06% in the GNE.
    explanation: The abstract confirms that Juvenile Huntington's Disease is
      rare, begins early, and progresses rapidly, supporting the statement.
  - reference: PMID:14584235
    supports: SUPPORT
    snippet: The presentation of juvenile Huntington's disease can cause
      diagnostic difficulties. The genetics and pathogenesis of the condition
      are discussed.
    explanation: The abstract acknowledges the existence of juvenile
      Huntington's disease, which supports the statement.
  - reference: PMID:2942452
    supports: SUPPORT
    snippet: Of 195 cases of juvenile Huntington disease gathered from case
      descriptions... It is argued that juvenile Huntington disease should not
      be regarded as a separate clinical entity, but as a manifestation of the
      rigid variant of the disease.
    explanation: The abstract discusses juvenile Huntington's disease and its
      characteristics, supporting the statement.
- name: Late-Onset Huntington's Disease
  description: Typically begins after the age of 50 and may have a slower
    progression.
  evidence:
  - reference: PMID:28671137
    supports: PARTIAL
    snippet: 'BACKGROUND: Although the typical age of onset for Huntington''s disease
      (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have
      a late onset (over 60 years of age).'
    explanation: The statement that Huntington's Disease typically begins after
      the age of 50 is not entirely accurate. While late-onset Huntington's
      Disease (LoHD) does occur, the typical age of onset for HD is in the
      fourth decade. However, the statement is partially supported by the fact
      that some individuals do experience late onset, and LoHD may have a slower
      progression.
  - reference: PMID:17390259
    supports: REFUTE
    snippet: Huntington's disease may present at any age, but most typically
      manifests between the ages of 35 and 45 years as a slowly progressive
      neurodegenerative movement disorder with cognitive and behavioral
      impairment.
    explanation: This reference refutes the statement that Huntington's Disease
      typically begins after the age of 50. It states that HD most typically
      manifests between the ages of 35 and 45 years.
  - reference: PMID:36318082
    supports: NO_EVIDENCE
    snippet: Juvenile-onset Huntington's disease (JOHD) is a rare form of
      Huntington's disease (HD) characterized by symptom onset before the age of
      21 years.
    explanation: This reference discusses Juvenile-onset Huntington's Disease,
      which is not relevant to the claim about typical onset after the age of
      50.
  - reference: PMID:28087720
    supports: NO_EVIDENCE
    snippet: Following predictive testing for Huntington disease (HD), knowledge
      of one's carrier status may have consequences on disease onset.
    explanation: This reference does not provide information relevant to the
      typical age of onset or progression of Huntington's Disease.
prevalence:
- population: Global
  percentage: 0.004-0.01
  evidence:
  - reference: PMID:1535611
    supports: PARTIAL
    snippet: It is concluded that most European populations, both Northern and
      Southern, show a relatively high prevalence (4-8 per 100,000), and that
      the disorder may also be frequent in India and parts of central Asia. HD
      is notably rare in Finland and in Japan, but data for Eastern Asia and
      Africa are inadequate.
    explanation: The prevalence of Huntington's Disease varies significantly
      across different regions, with some populations showing higher prevalence
      and others showing lower. Therefore, a global percentage of 0.004-0.01 may
      not accurately reflect the variability seen in different regions.
  - reference: PMID:28671137
    supports: NO_EVIDENCE
    snippet: Although the typical age of onset for Huntington's disease (HD) is
      in the fourth decade, between 4.4-11.5% of individuals with HD have a late
      onset (over 60 years of age).
    explanation: This reference discusses the age of onset and not the global
      prevalence.
inheritance:
- name: Autosomal Dominant
  evidence:
  - reference: PMID:29325616
    supports: SUPPORT
    snippet: Huntington disease is a monogenic neurodegenerative disorder that
      displays an autosomal-dominant pattern of inheritance.
    explanation: The literature explicitly states that Huntington's disease
      follows an autosomal-dominant pattern of inheritance.
  - reference: PMID:28803251
    supports: SUPPORT
    snippet: Huntington's disease (HD) is an autosomal dominant
      neurodegenerative disorder caused by the abnormal expansion of CAG triplet
      repeat.
    explanation: The literature confirms that Huntington's disease is an
      autosomal dominant disorder.
  - reference: PMID:36352624
    supports: SUPPORT
    snippet: Huntington's Disease (HD) is an autosomal dominant, progressive
      neuropsychiatric illness caused by CAG repeat expansion.
    explanation: The literature supports that Huntington's disease is inherited
      in an autosomal dominant manner.
pathophysiology:
- name: CAG Repeat Expansion in the HTT Gene
  description: Mutation characterized by an expanded number of CAG repeats,
    which encodes an abnormal polyglutamine tract in the huntingtin protein.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000955
      label: cerebral cortex
  biological_processes:
  - preferred_term: DNA mismatch repair
    term:
      id: GO:0006298
      label: mismatch repair
  evidence:
  - reference: PMID:7620118
    supports: SUPPORT
    snippet: Early in 1993, an unstable, expanded trinucleotide repeat in a
      novel gene of unknown function was identified on HD chromosomes. This
      discovery unleased a flurry of experimentation that has established the
      expanded CAG repeat the almost universal cause of the characteristic
      neurologic symptoms and pathology of this neurodegenerative disorder of
      midlife onset.
    explanation: The reference confirms that an expanded CAG repeat in the HTT
      gene is the cause of Huntington's Disease.
  - reference: PMID:35395060
    supports: SUPPORT
    snippet: Huntington's disease (HD) is caused by an expansion of the CAG
      trinucleotide repeat domain in the huntingtin gene that results in
      expression of a mutant huntingtin protein (mHTT) containing an expanded
      polyglutamine tract in the amino terminus.
    explanation: The literature clearly states that HD is caused by an expanded
      CAG repeat in the HTT gene, leading to a mutant huntingtin protein with an
      abnormal polyglutamine tract.
  - reference: PMID:27529325
    supports: SUPPORT
    snippet: Huntington's disease (HD) belongs to the group of inherited
      polyglutamine (PolyQ) diseases caused by an expanded CAG repeat in the
      coding region of the Huntingtin (HTT) gene that results in an elongated
      polyQ stretch.
    explanation: This reference supports the statement by specifying that HD is
      caused by an expanded CAG repeat in the HTT gene, leading to an elongated
      polyglutamine stretch.
  - reference: PMID:33579866
    supports: SUPPORT
    snippet: Huntington's disease (HD) (OMIM 143100) is caused by an expanded
      CAG repeat tract in the HTT gene.
    explanation: The reference supports the statement, confirming that HD is
      caused by an expanded CAG repeat in the HTT gene.
  - reference: PMID:31398342
    supports: SUPPORT
    snippet: Variable, glutamine-encoding, CAA interruptions indicate that a
      property of the uninterrupted HTT CAG repeat sequence, distinct from the
      length of huntingtin's polyglutamine segment, dictates the rate at which
      Huntington's disease (HD) develops.
    explanation: This reference supports the statement by discussing the role of
      uninterrupted CAG repeats in the HTT gene in the development of HD.
- name: Mutant Huntingtin Protein Aggregation
  description: Aggregates of mutant huntingtin protein lead to neuronal
    dysfunction and death, particularly in the striatum and cerebral cortex.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000955
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  evidence:
  - reference: PMID:35319359
    supports: SUPPORT
    snippet: Pathogenesis of HD involves cleavage of the huntingtin protein
      followed by the neuronal accumulation of its aggregated form.
    explanation: The literature supports that the pathogenesis of Huntington's
      Disease involves the accumulation of aggregated mutant huntingtin protein,
      leading to neuronal dysfunction and death.
  - reference: PMID:12657365
    supports: SUPPORT
    snippet: The initial and primary target of degeneration in HD is the
      striatal medium spiny GABAergic neuron, and by end stages of the disease
      up to 95% of these neurons are lost.
    explanation: This reference supports the statement by highlighting the
      primary degeneration of neurons in the striatum due to Huntington's
      Disease.
  - reference: PMID:31813995
    supports: SUPPORT
    snippet: Mutant HTT (mHTT) toxicity is caused by its
      aggregation/oligomerization. The striatum is the most vulnerable region,
      although all brain regions undergo neuronal degeneration in the disease.
    explanation: This literature supports the statement by confirming that
      mutant huntingtin protein aggregation leads to neurotoxicity, particularly
      in the striatum.
  - reference: PMID:23423362
    supports: SUPPORT
    snippet: Evaluation of postmortem HD tissue indicates that the most
      prominent cell loss occurs in cerebral cortex and striatum, forebrain
      regions in which cortical pyramidal neurons (CPNs) and striatal medium
      spiny neurons (MSNs) are the most affected.
    explanation: This reference supports the statement by indicating significant
      neuronal loss in the striatum and cerebral cortex in Huntington's Disease.
  - reference: PMID:24048953
    supports: SUPPORT
    snippet: Huntington's disease is caused by the expansion of a polyglutamine
      repeat (>37 glutamines) in the disease protein huntingtin, which results
      in preferential neuronal loss in distinct brain regions.
    explanation: The literature supports the statement by confirming that mutant
      huntingtin protein causes neuronal loss in specific brain regions,
      including the striatum and cerebral cortex.
- name: Excitotoxicity
  description: Overactivation of glutamate receptors leading to neuronal damage.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  - preferred_term: excitatory postsynaptic potential
    term:
      id: GO:0060079
      label: excitatory postsynaptic potential
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:38776957
    supports: SUPPORT
    snippet: We have identified transcriptional upregulation of genes encoding
      N-methyl-D-aspartate (NMDA),
      alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
      kainate receptors in medium spiny neurons, the cell type preferentially
      lost early in HD.
    explanation: The study identifies upregulation of glutamate receptors in
      medium spiny neurons, supporting the idea of excitotoxicity due to
      overactivation of these receptors leading to neuronal damage.
  - reference: PMID:1464368
    supports: SUPPORT
    snippet: Excitotoxicity refers to neuronal cell death caused by activation
      of excitatory amino acid receptors. A substantial body of evidence has
      implicated excitotoxicity as a mechanism of cell death in both acute and
      chronic neurologic diseases.
    explanation: This reference explains the concept of excitotoxicity and
      supports the idea that overactivation of glutamate receptors can lead to
      neuronal damage.
  - reference: PMID:7590394
    supports: SUPPORT
    snippet: Our results indicated that elevated glutamate concentrations (15
      mM, 1.5 mM, and 150 microM glutamate in perfusing solutions) would
      significantly increased both the concentrations of 2,3 and 2,5 DHBA.
    explanation: The study provides direct evidence that elevated glutamate
      levels increase the formation of hydroxyl radicals, implying oxidative
      stress induced by excitotoxicity, which supports the statement.
  - reference: PMID:19805493
    supports: SUPPORT
    snippet: Induction of striatal excitotoxicity in CB(2) receptor-deficient
      mice by quinolinic acid administration exacerbated brain oedema,
      microglial activation, proinflammatory-mediator state and medium-sized
      spiny neuron degeneration.
    explanation: This study shows that excitotoxicity induced in the striatum
      leads to medium spiny neuron degeneration, supporting the idea of
      excitotoxicity causing neuronal damage in Huntington's Disease.
- name: Mitochondrial Dysfunction
  description: Reduced efficiency of oxidative phosphorylation complexes, loss
    of mitochondrial membrane potential, and impaired mitochondrial DNA
    stability leading to bioenergetic failure.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000955
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
- name: Neuroinflammation
  description: Activation of microglia and astrocytes with neuroinflammatory
    responses occurring early in disease progression, contributing to
    neurodegeneration.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
- name: D2 Receptor Medium Spiny Neuron Selective Vulnerability
  description: D2 receptor-expressing medium spiny neurons show earlier
    huntingtin aggregation and greater sensitivity to CAG somatic instability
    compared to D1 receptor-expressing neurons.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0001880
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  - preferred_term: synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
phenotypes:
- name: Chorea
  evidence:
  - reference: PMID:24176425
    supports: SUPPORT
    snippet: Huntington disease (HD) is an autosomal dominant, adult-onset,
      progressive neurodegenerative disease characterized by the triad of
      abnormal movements (typically chorea), cognitive impairment, and
      psychiatric problems.
    explanation: The reference clearly states that chorea is a characteristic
      abnormal movement in Huntington's Disease.
  - reference: PMID:36049455
    supports: SUPPORT
    snippet: Chorea is one of the major manifestations of Huntington's disease.
    explanation: This reference confirms that chorea is a major manifestation of
      Huntington's Disease.
  - reference: PMID:31707371
    supports: SUPPORT
    snippet: 'BACKGROUND: Anosognosia, or unawareness of illness of deficits, has
      been observed in Huntington''s disease (HD) in relation to motor and cognitive
      signs and symptoms. Most studies of awareness in HD have used self-report questionnaire
      methodology rather than asking patients to report on their symptoms in real-time.
      The two studies in which patients were asked about their chorea in real-time
      had small sample sizes and only examined patients early in disease progression.'
    explanation: The reference mentions chorea in the context of Huntington's
      Disease, supporting the statement.
  - reference: PMID:6446233
    supports: SUPPORT
    snippet: Huntington's disease (chorea) is characterized by abnormal
      movements and dementia.
    explanation: This reference directly associates Huntington's Disease with
      chorea.
  - reference: PMID:32699773
    supports: SUPPORT
    snippet: Huntington's Disease (HD) is an autosomal dominant
      neurodegenerative disorder with a progressive decline in cognitive, motor,
      and psychological function. Chorea tends to be the most common associated
      movement disorder, although other variants of several abnormal movements
      are also seen.
    explanation: The reference states that chorea is the most common associated
      movement disorder in Huntington's Disease.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
- name: Dystonia
  description: Involuntary muscle contractions causing twisting and repetitive
    movements or abnormal postures.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
- name: Bradykinesia
  description: Slowness of movement, a common motor symptom in Huntington's
    Disease.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
- name: Cognitive Impairment
  description: Progressive decline in cognitive function affecting memory,
    executive function, and other cognitive domains.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
- name: Depression
  description: Mood disorder characterized by persistent sadness and loss of
    interest, common psychiatric manifestation in HD.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
- name: Weight Loss
  description: Progressive unintentional weight loss due to metabolic changes
    and systemic effects.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- name: Dysphagia
  description: Difficulty swallowing that occurs in later stages of the disease.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
biochemical:
- name: Elevated Neuronal Inclusions
  presence: Positive
  notes: Aggregates of mutant huntingtin protein found in neurons.
  evidence:
  - reference: PMID:22200539
    supports: SUPPORT
    snippet: Here we will review the state of knowledge of HD, focusing
      especially on a hallmark pathological feature-intracellular aggregates of
      mutant Htt called inclusion bodies (IBs).
    explanation: The article discusses the presence of intracellular aggregates
      of mutant huntingtin, which are referred to as inclusion bodies,
      supporting the statement.
  - reference: PMID:38810948
    supports: SUPPORT
    snippet: We confirmed the presence of mHtt aggregates within grafts of all
      three cases as well as tau neuropil threads in the grafts of two of the
      three transplanted HD patients.
    explanation: The study confirms the presence of mutant huntingtin (mHtt)
      aggregates within neurons, supporting the statement.
  - reference: PMID:19172113
    supports: SUPPORT
    snippet: It is likely that the aggregates containing expanded huntingtin are
      toxic to neurons, but it remains to be determined whether the oligomer or
      the inclusion is the toxic species.
    explanation: The article mentions that aggregates containing expanded
      huntingtin are found in neurons, supporting the statement.
  - reference: PMID:27886014
    supports: SUPPORT
    snippet: Using highly sensitive immunohistochemical methods we have detected
      the appearance of diffuse aggregates during embryonic development in the
      R6/2 and YAC128 mouse models of HD.
    explanation: The study observes the formation of aggregates in neuronal
      cells during embryonic development in mouse models of HD, supporting the
      statement.
genetic:
- name: HTT
  association: Pathogenic CAG Repeat Expansion
  notes: Primary causal gene encoding huntingtin protein; CAG repeat expansion
    leads to polyglutamine tract elongation.
  inheritance:
  - name: Autosomal Dominant
  evidence:
  - reference: PMID:27188817
    supports: SUPPORT
    snippet: Huntington disease is devastating to patients and their families -
      with autosomal dominant inheritance... The disease is caused by an
      expanded CAG trinucleotide repeat (of variable length) in HTT, the gene
      that encodes the protein huntingtin.
    explanation: The literature explicitly states that Huntington's disease is
      caused by an expanded CAG trinucleotide repeat in the HTT gene and is
      inherited in an autosomal dominant manner.
  - reference: PMID:33579864
    supports: SUPPORT
    snippet: Huntington's disease (HD) is an autosomal dominant
      neurodegenerative disorder caused by the expansion of the HTT CAG repeat.
    explanation: This reference confirms that Huntington's disease is caused by
      the expansion of the HTT CAG repeat and follows an autosomal dominant
      inheritance pattern.
  - reference: PMID:31820322
    supports: SUPPORT
    snippet: Huntington's disease (HD) is a rare autosomal dominant
      neurodegenerative disorder caused by a CAG expansion greater than 35 in
      the IT-15 gene.
    explanation: This source supports the statement by indicating that
      Huntington's disease is an autosomal dominant disorder caused by a CAG
      expansion in the HTT gene.
  - reference: PMID:37863037
    supports: SUPPORT
    snippet: Among the CAG/polyQ repeat diseases are Huntington's disease (HD)
      and spinocerebellar ataxia type 1 (SCA1), in which the expansions are
      within widely expressed proteins. Although both HD and SCA1 are autosomal
      dominantly inherited...
    explanation: This reference supports the statement by confirming that
      Huntington's disease is among the CAG repeat diseases and is autosomal
      dominantly inherited.
  - reference: PMID:33579866
    supports: SUPPORT
    snippet: Huntington's disease (HD) (OMIM 143100) is caused by an expanded
      CAG repeat tract in the HTT gene. The inherited CAG length is known to
      expand further in somatic and germline cells in HD subjects.
    explanation: This source supports the statement by confirming that
      Huntington's disease is caused by an expanded CAG repeat in the HTT gene
      and follows an autosomal dominant inheritance pattern.
  - reference: PMID:36352624
    supports: SUPPORT
    snippet: Huntington's Disease (HD) is an autosomal dominant, progressive
      neuropsychiatric illness caused by CAG repeat expansion.
    explanation: This reference supports the statement by confirming that
      Huntington's disease is an autosomal dominant disorder caused by CAG
      repeat expansion.
  - reference: PMID:31263285
    supports: SUPPORT
    snippet: Huntington's disease (HD) is a dominantly inherited
      neurodegenerative disorder caused by a CAG trinucleotide expansion in the
      huntingtin gene (HTT)...
    explanation: This source supports the statement by confirming that
      Huntington's disease is caused by a CAG trinucleotide expansion in the HTT
      gene and follows an autosomal dominant inheritance pattern.
  - reference: PMID:31491822
    supports: SUPPORT
    snippet: The expression of the HTT CAG repeat expansion mutation causes
      neurodegeneration in Huntington's disease (HD).
    explanation: This reference supports the statement by confirming that the
      HTT CAG repeat expansion causes neurodegeneration in Huntington's disease.
  - reference: PMID:26439718
    supports: SUPPORT
    snippet: Huntington disease (HD) is caused by expansion of a CAG
      trinucleotide repeat in the first exon of the Huntingtin (HTT) gene.
    explanation: This source supports the statement by confirming that
      Huntington's disease is caused by the expansion of a CAG trinucleotide
      repeat in the HTT gene.
  - reference: PMID:28832564
    supports: SUPPORT
    snippet: Huntington's disease (HD) is an autosomal dominant
      neurodegenerative disease caused by expansion of a CAG trinucleotide
      repeat in HTT...
    explanation: This reference supports the statement by confirming that
      Huntington's disease is caused by the expansion of a CAG trinucleotide
      repeat in the HTT gene and is autosomal dominant.
- name: MSH3
  association: Genetic Modifier
  notes: DNA mismatch repair gene; modulates somatic CAG instability and
    influences age at onset via somatic expansion.
- name: MLH1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; drives somatic CAG expansion and
    significantly affects disease onset age and progression.
- name: PMS1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: PMS2
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: LIG1
  association: Genetic Modifier
  notes: DNA ligase gene; involved in DNA repair pathways that modulate somatic
    CAG instability.
- name: PPARGC1A
  association: Pathophysiological Role
  notes: PGC-1alpha gene; reduced expression contributes to bioenergetic failure
    and mitochondrial dysfunction in HD.
- name: SLC1A2
  association: Pathophysiological Role
  notes: EAAT2 glutamate transporter gene; impaired function contributes to
    excitotoxicity through reduced glutamate clearance.
- name: BDNF
  association: Pathophysiological Role
  notes: Brain-derived neurotrophic factor; impaired trophic signaling and
    transport from cortex to striatum contributes to neuronal vulnerability.
- name: NTRK2
  association: Pathophysiological Role
  notes: TrkB receptor gene; mediates BDNF signaling; impaired function
    contributes to reduced trophic support.
- name: DRD1
  association: Pathophysiological Role
  notes: Dopamine D1 receptor; marker of direct pathway medium spiny neurons.
- name: DRD2
  association: Pathophysiological Role
  notes: Dopamine D2 receptor; marker of indirect pathway medium spiny neurons
    which show earlier vulnerability and greater CAG instability.
- name: SQSTM1
  association: Pathophysiological Role
  notes: p62/SQSTM1 gene; autophagy adaptor protein; accumulation indicates
    autophagy-lysosomal pathway dysfunction.
environmental:
- name: None Applicable
  evidence:
  - reference: PMID:20591965
    supports: NO_EVIDENCE
    snippet: Huntington's disease.
    explanation: The provided reference does not mention anything about 'None
      Applicable' in relation to Huntington's Disease.
  - reference: PMID:1535663
    supports: NO_EVIDENCE
    snippet: What ethical justification can be found for informing a person that
      he or she will later develop a lethal disease for which no therapy is
      available?
    explanation: The provided reference discusses the ethics of genetic
      prediction and testing for Huntington's Disease but does not mention 'None
      Applicable' as a value.
  - reference: PMID:29856024
    supports: NO_EVIDENCE
    snippet: Huntington's disease (HD) is a monogenic, autosomal dominant
      inherited fatal disease that affects 1 in 10,000 people worldwide.
    explanation: The provided reference discusses nonhuman primate models for
      Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:18414297
    supports: NO_EVIDENCE
    snippet: Research into the experience of the Huntington's disease (HD)
      family caregiver has established that HD carers experience a number of
      unique obstacles within their caregiving role.
    explanation: The provided reference discusses the family aspects of
      Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:18846148
    supports: NO_EVIDENCE
    snippet: Huntington's disease is an autosomal dominant slowly degenerative
      apoptotic condition in CNS, in particular in striatum.
    explanation: The provided reference discusses the clinical and genetic
      aspects of Huntington's Disease but does not mention 'None Applicable' as
      a value.
  - reference: PMID:34842303
    supports: NO_EVIDENCE
    snippet: Huntington's disease (HD) is a rare neurodegenerative disorder with
      protean clinical manifestations.
    explanation: The provided reference discusses treatments for Huntington's
      Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:26569646
    supports: NO_EVIDENCE
    snippet: Huntington's disease is a neurodegenerative disorder caused by the
      expansion of a CAG triplet in the huntingtin gene.
    explanation: The provided reference discusses the role of periodontitis in
      Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:25164859
    supports: NO_EVIDENCE
    snippet: 'Huntington''s disease: a field on the move. Introduction.'
    explanation: The provided reference is an introduction to Huntington's
      Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:29737569
    supports: NO_EVIDENCE
    snippet: Huntington's disease is a progressive neurodegenerative disorder
      for which therapies are woefully inadequate and do not prevent inevitable
      progression.
    explanation: The provided reference discusses current and future therapeutic
      prospects for Huntington's Disease but does not mention 'None Applicable'
      as a value.
  - reference: PMID:32179957
    supports: NO_EVIDENCE
    snippet: In Germany at least 8000 and probably up to ca. 14,000 people
      currently suffer from clinically manifest Huntington's disease (HD).
    explanation: The provided reference discusses gene-selective treatment
      approaches for Huntington's Disease but does not mention 'None Applicable'
      as a value.
animal_models:
- species: Mouse
  genotype: R6/2 Transgenic
  description: Mice expressing human mutant huntingtin with expanded CAG repeats
    used to model motor and cognitive deficits.
  associated_phenotypes:
  - Progressive Motor Dysfunction
  - Cognitive Impairment
  - Weight Loss
  evidence:
  - reference: PMID:18638556
    supports: SUPPORT
    snippet: Huntington disease (HD) is a dominantly inherited human
      neurodegenerative disorder characterized by motor deficits, cognitive
      impairment, and psychiatric symptoms leading to inexorable decline and
      death. Since the identification of the huntingtin gene and the
      characteristic expanded CAG repeat/polyglutamine mutation, multiple murine
      genetic models and one rat genetic model have been generated.
    explanation: This reference supports the statement as it describes
      Huntington's disease as involving motor deficits and cognitive impairment,
      and mentions the use of murine genetic models, including transgenic ones
      with expanded CAG repeats like the R6/2 model.
  - reference: PMID:35007790
    supports: SUPPORT
    snippet: We used the R6/2 and BACHD mouse models that express different
      lengths of mutant HTT to develop lean- and obese phenotypes, respectively.
      We utilized adeno-associated viral vectors to overexpress either mutant or
      wild-type HTT in the hypothalamus of R6/2, BACHD, and their wild-type
      littermates. The metabolic phenotype was assessed by body weight
      measurements over time and body composition analysis using dual-energy
      x-ray absorptiometry at the endpoint.
    explanation: This reference supports the statement by describing the use of
      R6/2 mice, which express mutant HTT, to study metabolic phenotypes
      including weight changes, indicating weight loss as part of the disease
      phenotype.
  - reference: PMID:29856017
    supports: SUPPORT
    snippet: Motor deficits are a characteristic consequence of striatal damage,
      whether induced by experimental lesions, or in genetic models of
      Huntington's disease involving polyglutamine expansion in the huntingtin
      protein.
    explanation: This reference supports the statement by confirming that motor
      deficits are a characteristic consequence of genetic models of
      Huntington's disease, including those with polyglutamine expansion such as
      the R6/2 model.
  - reference: PMID:31868674
    supports: SUPPORT
    snippet: 'Huntington''s disease (HD) is a neurodegenerative disorder caused by
      the expansion of the trinucleotide CAG in the HD gene. While the presence of
      nuclear aggregates of mutant huntingtin (mHtt) in neurons is a hallmark of HD,
      the reason behind its toxicity remains elusive. OBJECTIVE: The present study
      was conducted to assess a correlation between the number of mHtt aggregates
      and the severity of HD symptoms in R6/1 mice.'
    explanation: This reference supports the statement by describing the use of
      R6/1 mice, a similar model to R6/2, to study the correlation between
      mutant huntingtin aggregates and the severity of HD symptoms, including
      motor and cognitive deficits.
  - reference: PMID:15525658
    supports: SUPPORT
    snippet: We describe for the first time a dramatic atrophy and loss of
      orexin neurons in the lateral hypothalamus of R6/2 mice. Importantly, we
      also found a significant atrophy and loss of orexin neurons in Huntington
      patients.
    explanation: This reference supports the statement by describing the use of
      R6/2 mice to model Huntington's disease, noting significant neuronal
      changes that correlate with the disease phenotype.
diagnosis:
- name: Genetic Testing for HTT CAG Expansion
  presence: Positive
  notes: Confirmation of diagnosis through DNA analysis.
  evidence:
  - reference: PMID:26439718
    supports: SUPPORT
    snippet: Huntington disease (HD) is caused by expansion of a CAG
      trinucleotide repeat in the first exon of the Huntingtin (HTT) gene.
      Molecular testing of Huntington disease for diagnostic confirmation and
      disease prediction requires detection of the CAG repeat expansion.
    explanation: The literature confirms that genetic testing for HTT CAG
      expansion is used for the diagnostic confirmation of Huntington's Disease.
  - reference: PMID:23390178
    supports: SUPPORT
    snippet: We analyzed the clinical and genetic characteristics of 76
      juvenile-onset patients referred consecutively for HD genetic testing over
      a 16-year period. ... All expanded cases had a family history of
      genetically confirmed HD compared to only 13.5% of unexpanded cases (p =
      0.000).
    explanation: This study supports the use of genetic testing for confirming
      the diagnosis of Huntington's Disease by identifying the CAG expansion.
  - reference: PMID:31820322
    supports: SUPPORT
    snippet: Huntington's disease (HD) is a rare autosomal dominant
      neurodegenerative disorder caused by a CAG expansion greater than 35 in
      the IT-15 gene.
    explanation: This reference supports the statement that Huntington's Disease
      is confirmed through genetic testing for HTT CAG expansion.
  - reference: PMID:28947110
    supports: SUPPORT
    snippet: The gene for HD was found in 1993, allowing for direct gene testing
      for the mutant HTT allele.
    explanation: The discovery of the HD gene allows for direct genetic testing
      to confirm the presence of HTT CAG expansion, supporting the statement.
- name: Neurological Examination
  notes: Assessment of motor disturbances, cognitive function, and psychiatric
    symptoms.
  evidence:
  - reference: PMID:29856017
    supports: SUPPORT
    snippet: Motor deficits are a characteristic consequence of striatal damage,
      whether induced by experimental lesions, or in genetic models of
      Huntington's disease involving polyglutamine expansion in the huntingtin
      protein.
    explanation: This reference supports the assessment of motor disturbances in
      Huntington's Disease.
  - reference: PMID:29278291
    supports: SUPPORT
    snippet: Cognitive impairment is one of the main features of Huntington's
      disease and is present across the disease spectrum.
    explanation: This reference supports the assessment of cognitive function in
      Huntington's Disease.
  - reference: PMID:30012004
    supports: SUPPORT
    snippet: This clinical update review focuses on the common neuropsychiatric
      manifestations in HD, and outlines and evaluates the various
      neuropsychiatric facets of HD, including the aetiology, symptoms and
      diagnosis.
    explanation: This reference supports the assessment of psychiatric symptoms
      in Huntington's Disease.
  - reference: PMID:31922295
    supports: SUPPORT
    snippet: To determine the relationships between the motor phenotype and the
      presence of specific neuropsychiatric and neuropsychological disorders in
      patients with early motor-manifest Huntington's disease.
    explanation: This reference supports the assessment of motor disturbances,
      cognitive function, and psychiatric symptoms in Huntington's Disease.
  - reference: PMID:36450478
    supports: SUPPORT
    snippet: Recent reports highlight the onset of cognitive and psychiatric
      symptoms before motor manifestations.
    explanation: This reference supports the assessment of cognitive function
      and psychiatric symptoms in Huntington's Disease.
treatments:
- name: Tetrabenazine
  role: Symptomatic
  description: Used to manage chorea by depleting dopamine.
  evidence:
  - reference: PMID:24366610
    supports: SUPPORT
    snippet: Tetrabenazine is a dopamine-depleting agent that may be one of the
      more effective agents for reducing chorea, although it has a risk of
      potentially serious adverse effects.
    explanation: This reference confirms that tetrabenazine is used to manage
      chorea in Huntington's Disease by depleting dopamine.
  - reference: PMID:20869622
    supports: SUPPORT
    snippet: Tetrabenazine (TBZ) is a monoamine-depleting agent initially
      studied in the 1950s and currently approved by the US Food and Drug
      Administration for the treatment of chorea in Huntington's disease.
    explanation: This reference confirms that tetrabenazine depletes monoamines,
      including dopamine, to manage chorea in Huntington's Disease.
  - reference: PMID:20442355
    supports: SUPPORT
    snippet: Tetrabenazine binds reversibly to the type 2 vesicular monoamine
      transporters and has been shown to inhibit monoamine uptake in presynaptic
      vesicles, resulting in monoamine depletion.
    explanation: This reference supports that tetrabenazine depletes dopamine to
      manage chorea in Huntington's Disease.
  - reference: PMID:27819145
    supports: SUPPORT
    snippet: Since the approval of tetrabenazine, the classic VMAT2 inhibitor,
      in the treatment of chorea associated with Huntington disease (HD)...
    explanation: This reference confirms that tetrabenazine, a VMAT2 inhibitor,
      is used to treat chorea in Huntington's Disease by depleting dopamine.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: tetrabenazine
      term:
        id: CHEBI:9467
        label: tetrabenazine
- name: Antipsychotic Medications
  role: Symptomatic
  description: Used for psychiatric symptoms like irritability and agitation.
  evidence:
  - reference: PMID:27534434
    supports: SUPPORT
    snippet: In clinical practice antipsychotics represent the first choice in
      the management of chorea in the presence of psychiatric symptoms...
    explanation: The literature states that antipsychotics are used to manage
      psychiatric symptoms in Huntington's Disease.
  - reference: PMID:16383221
    supports: SUPPORT
    snippet: According to clinical observation, HD patients with psychiatric
      symptoms respond to standard pharmacotherapy.
    explanation: The literature supports the use of pharmacotherapy, which
      includes antipsychotic medications, for psychiatric symptoms in
      Huntington's Disease.
  - reference: PMID:36496108
    supports: SUPPORT
    snippet: Several lines of evidence suggest a possible role of risperidone
      via the antagonistic effect of Dopamine D2 and 5HT-receptor in different
      neurological diseases like cognitive dysfunction of schizophrenia,
      neuroinflammation, Huntington's disease...
    explanation: Risperidone, an antipsychotic, is mentioned as having a role in
      treating psychiatric symptoms in Huntington's Disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Selective Serotonin Reuptake Inhibitors (SSRIs)
  role: Symptomatic
  description: Used to manage depression.
  evidence:
  - reference: PMID:18394562
    supports: SUPPORT
    snippet: Several classes of medications have been used to ameliorate the
      various symptoms of HD, including typical and atypical neuroleptics,
      dopamine depleters, antidepressants...
    explanation: The abstract mentions that antidepressants, which include
      SSRIs, are used to manage symptoms in Huntington's Disease.
  - reference: PMID:22119091
    supports: SUPPORT
    snippet: Cross-sectionally, suicidal mutation carriers were more likely to
      use antidepressants (odds ratio=5.3)...
    explanation: The use of antidepressants, which can include SSRIs, is
      associated with managing depressive symptoms in Huntington's Disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Physical Therapy
  role: Supportive
  description: Helps maintain mobility and function.
  evidence:
  - reference: PMID:31907286
    supports: SUPPORT
    snippet: There is strong evidence to support physical therapy interventions
      to improve fitness, motor function, and gait in persons with HD.
    explanation: The review provides strong evidence that physical therapy
      interventions improve fitness, motor function, and gait in people with
      Huntington's Disease, supporting the statement that physical therapy helps
      maintain mobility and function.
  - reference: PMID:31177235
    supports: SUPPORT
    snippet: Prior Huntington''s disease (HD) studies suggest ancillary services
      improve motor symptoms, cognition, mood, and quality of life.
    explanation: The study indicates that ancillary services, which include
      physical therapy, improve motor symptoms in HD patients, supporting the
      statement that physical therapy helps maintain mobility and function.
  - reference: PMID:25062860
    supports: SUPPORT
    snippet: TUG (beta 0.46, CI 0.20-3.47), BBS (beta -0.35, CI -2.10-0.14), and
      TMT (beta -0.45, CI -3.14-0.64) were good disease-specific mobility
      measures.
    explanation: The study identifies specific mobility measures that are
      effective for assessing and optimizing mobility in HD patients, supporting
      the statement that physical therapy helps maintain mobility and function.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Speech Therapy
  role: Supportive
  description: Helps manage dysarthria and dysphagia.
  evidence:
  - reference: PMID:28983422
    supports: PARTIAL
    snippet: SLPs play an important role in the evaluation and management of
      dysarthria and dysphagia.
    explanation: The literature indicates that speech-language pathologists
      (SLPs) play a significant role in managing dysarthria and dysphagia in
      patients with hyperkinetic disorders, including Huntington's Disease.
      However, it does not explicitly state that speech therapy helps manage
      these conditions in HD specifically.
  - reference: PMID:33577706
    supports: PARTIAL
    snippet: Findings shed a light on everyday communication challenges faced by
      people with HD and their professional caregivers, and the lack of
      implementation of communication aids in this group.
    explanation: The literature highlights the importance of including speech
      and language therapists in the care of HD patients, indicating a
      supportive role. However, it does not provide explicit evidence that
      speech therapy directly helps manage dysarthria and dysphagia in HD.
  - reference: PMID:31989345
    supports: NO_EVIDENCE
    snippet: The impact of pharmacological and rehabilitative treatments on
      dysphagia in HD has been little studied in literature.
    explanation: The literature states that the impact of rehabilitative
      treatments, including speech therapy, on dysphagia in HD has been
      minimally studied, providing no clear evidence of its efficacy.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Occupational Therapy
  role: Supportive
  description: Assists with daily living activities.
  evidence:
  - reference: PMID:28947114
    supports: PARTIAL
    snippet: Lifestyle factors, such as activity level and exercise, as well as
      specific motor training may be helpful in managing the functional sequelae
      of HD and possibly slowing disease progression.
    explanation: The literature suggests that rehabilitation interventions,
      including motor training, can help manage functional abilities in HD,
      which implies a supportive role in daily living activities. However, it
      does not explicitly mention occupational therapy or daily living
      activities directly.
  - reference: PMID:36055643
    supports: PARTIAL
    snippet: This objective burden increased with higher functional loss of the
      HD individual and with more severe cognitive-behavioral disorders.
    explanation: This study discusses the burden on informal caregivers and the
      functional loss in HD individuals, indicating a need for supportive roles,
      which could include occupational therapy. However, it does not explicitly
      mention occupational therapy.
  - reference: PMID:31177235
    supports: SUPPORT
    snippet: Prior Huntington's disease (HD) studies suggest ancillary services
      improve motor symptoms, cognition, mood, and quality of life but frequency
      of use and clinicalcharacteristics are unclear.
    explanation: The literature explicitly mentions that ancillary services,
      which include occupational therapy, improve various aspects of life for HD
      patients, indicating a supportive role in daily living activities.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Genetic Counseling
  role: Supportive
  description: Provides information and support regarding inheritance patterns,
    predictive testing, and family planning for individuals at risk or affected
    by HD.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
review_notes: Huntington's Disease is a progressive neurodegenerative disorder
  characterized by a triad of motor, cognitive, and psychiatric symptoms. The
  genetic basis and impactful phenotypes have been summarized. Further research
  on therapeutic interventions is ongoing, focusing on disease-modifying
  treatments.
disease_term:
  preferred_term: Huntington disease
  term:
    id: MONDO:0007739
    label: Huntington disease
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
  - classification_value: neurodegenerative disease
  - classification_value: movement disorder
references:
- reference: DOI:10.21608/rpbs.2025.410003.1392
  title: Molecular and Cellular Insights into Huntingtons Disease
    Pathophysiology
  findings: []
- reference: DOI:10.3389/fncel.2023.1094503
  title: Striatal spatial heterogeneity, clustering, and white matter
    association of GFAP+ astrocytes in a mouse model of Huntingtons disease
  findings: []
- reference: DOI:10.3390/biology14020129
  title: 'Advances in Huntingtons Disease Biomarkers: A 10-Year Bibliometric Analysis
    and a Comprehensive Review'
  findings: []
- reference: DOI:10.3390/genes15060807
  title: 'Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease'
  findings: []
- reference: DOI:10.3390/ijms25073845
  title: 'Huntingtons Disease: Complex Pathogenesis and Therapeutic Strategies'
  findings: []
- reference: DOI:10.3390/ijms252111787
  title: 'Neuroinflammatory Proteins in Huntingtons Disease: Insights into Mechanisms,
    Diagnosis, and Therapeutic Implications'
  findings: []
